PharmRep Direct from the editors of Pharmaceutical Representative

September 02, 2010 Issue 41 Vol. 8	www.pharmrep.com
Contact Editor: Reid Paul

Genzyme to Sanofi: $18.5 Billion Isn’t Enough
Sanofi Aventis’ offer doesn’t appear to be enough for it to get into bed with the genetic disease drug manufacturer
ť MORE

FDA Warns Baxter for Misleading Promotional Materials
FDA letter to Baxter International over claims about its lung drug is company’s third warning in just over two years
ť MORE

Pfizer Adds FoldRx to Specialty Care Unit
The drug giant nabbed protein-folding drug firm FoldRx to help bolster its specialty care division that focuses on orphan and rare diseases
ť MORE

Target Practice
Sales numbers have long been the driver of rep compensation. Can pharma find new targets that won’t miss the mark?
ť MORE

Let the Sunshine In
The Physician Payment Sunshine Act is a game changer for medical marketing and sales reps
ť MORE

Leave the Samples Behind
As access decreases inside sales provides a new way to deliver information to physicians
ť MORE

Study Shows Spike in Branded Drug Price

No Decision on Reuters Job Cuts

Fewer Pharma Layoffs in August

Follow Pharm Rep on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.